Document Detail


Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
MedLine Citation:
PMID:  9860377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effectiveness of plasma cholesterol reduction therapy is no longer in question. Recent studies of cholesterol-lowering drug therapy demonstrate significant reductions in risks of mortality and coronary events in patients with existing coronary artery disease. The West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the therapy's effectiveness as primary prevention in patients without demonstrated coronary artery disease. Now that the efficacy of lipid reduction has been demonstrated conclusively, we face the difficult question of deciding what the treatment goals should be, whom to treat, and how to make those decisions cost effectively. These questions have complex social and ethical components and will lead to considerable discussion about how lipid-decreasing drugs will be used.
Authors:
J Shepherd
Related Documents :
9386157 - Association between serum amyloid a proteins and coronary artery disease: evidence from...
3059787 - Review of major intervention studies in hypertension and hyperlipidemia: focus on coron...
19816987 - Statins as anti-arrhythmics: a systematic review part ii: effects on risk of ventricula...
16061117 - Preoperative statin use and outcomes following cardiac surgery.
1721127 - Repetitive nonsustained monomorphic ventricular tachycardia aborted by methoxamine and ...
2862707 - Angina after aortocoronary bypass grafting: combined medical therapy including nifedipine.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  82     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1999-01-06     Completed Date:  1999-01-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  57T-59T     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathological Biochemistry, University of Glasgow, Scotland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / economics,  therapeutic use*
Cholesterol, LDL / blood
Coronary Disease / economics,  mortality,  prevention & control*
Double-Blind Method
Female
Follow-Up Studies
Humans
Hypercholesterolemia / drug therapy*
Male
Middle Aged
Pravastatin / economics,  therapeutic use*
Primary Prevention / economics
Randomized Controlled Trials as Topic
Scotland
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
Next Document:  The new pathophysiology of coronary artery disease.